Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Imidazoline receptor ligands act on the I1, I2 and I3 binding sites for imidazoline compounds. Imidazoline receptors were proposed when clonidine-like compounds were found to lower blood pressure through brainstem sites distinct from α2-adrenergic receptors. I1 sites take part in central blood pressure control, and I2 sites are linked to monoamine oxidase. I3 sites in pancreatic β cells are involved in the regulation of insulin secretion. Moxonidine hydrochloride and rilmenidine phosphate are listed as I1 agonists, and AGN 192403 as an I1 antagonist. Idazoxan hydrochloride blocks α2-adrenergic receptors and binds I2 sites, as does BU226 hydrochloride, while KU14R is an I3 antagonist. Clonidine hydrochloride and guanabenz acetate act mainly at α2-adrenergic receptors and are also listed under Adrenergic Receptors.
Moxonidine is a new-generation centrally-acting antihypertensive drug. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction.
